BROMODEOXYURIDINE AND RADIATION THERAPY FOR CARCINOMA OF THE CERVIX, VAGINA

溴脱氧尿嘧啶和放射治疗宫颈癌、阴道癌

• 批准号: 6113359
• 负责人: Avraham Eisbruch
• 金额: $ 2.14万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6113359
• 关键词: bromodeoxyuridine; carcinoma; cervix neoplasms; clinical research; clinical trials; combination cancer therapy; drug administration rate /duration; drug screening /evaluation; endometrium; female; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; uterus neoplasms; vagina neoplasms; women's health

Preclinical data has shown that administering RT and thymidine analog radiosensitizer in an alternating weekly schedule may allow clinically significant radiosensitization without markedly increased toxicity. This is a dose seeking trial of the use of the thymidine analog bromodeoxyuridine (BrdUrd) and RT for the treatment of patients with locally advanced or recurrent carcinoma of the cervix, vagina and endometrium.

临床前数据显示，给予RT和胸苷类似物 每周交替服用放射增敏剂可能会在临床上 有显著的放射增敏作用，但毒性没有明显增加。 这是对胸腺嘧啶核苷类似物使用的剂量寻求试验。 溴脱氧尿嘧啶核苷(BrdUrd)联合RT治疗慢性阻塞性肺疾病 局部晚期或复发的宫颈癌、阴道癌和 子宫内膜。